Revenue Update on OHR Pharmaceutical Inc(NASDAQ:OHRP)

OHR Pharmaceutical Inc(NASDAQ:OHRP) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during After-hours on Aug 9, 2016. Earnings per share were $-0.24. Analysts had estimated an EPS of $-0.27.

OHR Pharmaceutical Inc (OHRP) remained unchanged at the close of Wednesday session. Even as the volume increased to 37,408 ,the shares failed to make any impression and ended at 0 points or 0.00% at $2.64. The trading session commenced at $2.62 and the stock hit a high of $2.68 and touched $2.62 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $6.56 and the 52-week low is $2.25. The company has a market cap of $85 M and has approximately 3,21,03,969 outstanding shares.

Several Insider Transactions has been reported to the SEC. On Jun 21, 2016, Jason Scott Slakter (CEO) purchased 8,786 shares at $2.84 per share price.Also, On Jun 21, 2016, Samuel Backenroth (Chief Financial Officer) purchased 2,468 shares at $2.84 per share price.On Feb 10, 2015, Irach B. Taraporewala (CEO) purchased 3,705 shares at $6.75 per share price, according to the Form-4 filing with the securities and exchange commission.

Ohr Pharmaceutical Inc. is a pharmaceutical company. The Company is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of various programs and indications at various stages of development. The Company’s clinical program OHR-102 eye drops is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Company focuses on OHR-102 eye drops which is given in combination with Lucentis injections for the treatment of retinal diseases including wet-age-related macular degeneration (AMD) retinal vein occlusion and proliferative diabetic retinopathy. The Company’s product pipeline also includes SKS Sustained Release Ocular Drug Delivery Platform Technology Animal Model for Dry-AMD and Non-Ophthalmology Assets. OHR-102 is a small molecule anti-angiogenic drug with an intracellular mechanism of action.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *